- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04579731
Development of Fecal Scoring for the Management of Fecal Impaction With Regards to Lower Urinary Tract Dysfunction
Study Overview
Status
Intervention / Treatment
Detailed Description
Functional constipation is a common disorder among children, accounting for 3-5% of visits to pediatric clinics and even 10% to 25% of consultation for pediatric gastroenterologists. It could cause recurrent abdominal pain, stool retention as well as fecal incontinence. In the urologic field, this is known to develop urinary symptoms. Constipation has been associated with voiding dysfunction and urinary tract infection in children. It is assumed that impacted stool in distal rectum mechanically affect the bladder leading to detrusor overactivity. Additionally, impacted stool would elevate the uretheral sphincter tone, having patients void with incomplete sphincter relaxation and eliciting dysfunctional voiding. Stool impaction may be the source of bacteria causing urinary tract infection and led to recurrent bacteriuria. Treatment of constipation by itself is quite effective alleviating urologic symptoms in as much as two-third of the patients.
The role of constipation has been highlighted as a major player in vesicoureteral reflux and urinary tract infection (UTI). The presence of bowel bladder disorder (BBD) was associated with higher risk of breakthrough infection and a lack of spontaneous resolution. Although constipation is the major player in BBC, there is any objective standard regarding the diagnosis and treatment of constipation. Given the high prevalence and morbidity of children affected by UTI or VUR in relations to BBD, it is imperative that diagnostic and treatment methods are developed.
Despite the known implication of constipation, the diagnosis of constipation may be problematic due to a lack of standard definition for this condition. This may be due to different views between clinicians about which aspect are most crucial for diagnosing constipation. Some underline the subjective nature such as infrequent or difficult defecation, other stress the quality of stool, still others were in search of objective criteria of constipation, like the amount of impacted stool or colonic transit time. Consequently, various criteria have been reported.
The lack of standard criteria for constipation causes trouble sometimes in making a proper decision for diagnosis, intervention, follow-up, and discharge of treatment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with having both significant Lowery Urinary Tract Dysfunction history suggestive of constipation (more than two positive criteria in ROME 4).
- Parental recalling of hard stool (Bristol stool scale of 6 or 7).
- Parental impression of constipation.
Exclusion Criteria:
- Those without Lower Urinary Tract Dysfunction or constipation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fecal Impaction (LUTD-FI)
Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks.
Following eight weeks of treatment, patients were re-evaluated and those with 50% of symptom improvement were assumed to have a significant improvement attributable to the development of Lower Urinary Tract Dysfunction- Fecal Impaction (LUTD-FI).
|
|
Lower Urinary Tract Dysfunction Not Related to Fecal Impaction
Patients with both significant Lower Urinary Tract Dysfunction history suggestive of constipation were treated with lactitol monohydrate syrup 10 g for eight weeks.
Following eight weeks of treatment, patients were re-evaluated and those without symptom improvement place into lower urinary tract dysfunction not related to fecal impaction (LUTD-FI).
They serve as a control group.
|
Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
KUB (Kidneys, Ureters, Bladder)
Time Frame: After 8 weeks from the baseline
|
Examine the outcomes of the treatment of lactitol monohydrate 10 g in relation to Lower Urinary Tract Dysfunction and fecal impaction by using KUB (Kidneys, Ureters, Bladder) x-ray images.
|
After 8 weeks from the baseline
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008-133-1150
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowel Dysfunction
-
Halil TugtepeBahçeşehir UniversityCompletedBladder and Bowel Dysfunction, Femoral Anteversion | Bladder and Bowel Dysfunction, Hip Strength Ratios | Bladder and Bowel Dysfunction, Pelvic AngleTurkey
-
Children's Hospital of Orange CountyEnrolling by invitationBladder and Bowel DysfunctionUnited States
-
Bausch Health Americas, Inc.CompletedPost Operative Bowel DysfunctionGermany, Italy, United States, Hungary, Korea, Republic of, South Africa, Poland, Australia, Romania, Former Serbia and Montenegro
-
VA Office of Research and DevelopmentCompleted
-
Hasan Kalyoncu UniversityCompleted
-
VA Office of Research and DevelopmentNot yet recruiting
-
National Academy of Medical Sciences, NepalCompletedSexual Dysfunction | Colorectal Surgery | Bowel Dysfunction | Bladder Dysfunction
-
University of NottinghamLesaffre InternationalWithdrawnIrritable Bowel Syndrome | Post Infective Bowel DysfunctionUnited Kingdom
-
University of NottinghamKing's College London; Nottingham University Hospitals NHS TrustTerminatedFunctional Gastrointestinal Disorders | Post-infective Bowel DysfunctionUnited Kingdom
-
Pelvalon, Inc.CompletedFecal Incontinence | Bowel Dysfunction | Bowel Incontinence | Accidental Bowel LeakageUnited States
Clinical Trials on Lactitol Monohydrate
-
Boston UniversityInnovations for Poverty ActionCompletedCardiovascular Disease | Breast Cancer | Asthma | Diabetes Type II
-
Assistance Publique - Hôpitaux de ParisInstitute of Cardiometabolism and Nutrition, FranceTerminatedMetabolic Diseases | Obesity | Nutrition Disorders | Body WeightFrance
-
Leiden University Medical CenterErasmus Medical CenterCompleted
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisKorea, Republic of
-
Novartis VaccinesWithdrawn
-
Novartis VaccinesNovartisCompletedMeningococcal Disease | Meningococcal MeningitisUnited States
-
University of OxfordCompletedMeningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria MeningitidiUnited Kingdom
-
Instituto de Investigación Hospital Universitario...Unknown
-
Denovo Biopharma LLCCompleted
-
Cambridge University Hospitals NHS Foundation TrustGlaxoSmithKline; University of Cambridge; Royal Brompton & Harefield NHS Foundation... and other collaboratorsCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom